cGMP-dependent 3',5'-cyclic phosphodiesterase

Description:

Description
  • Accession: O00408
  • Swissprot: PDE2A_HUMAN
  • Organism: Homo sapiens
  • Gene: PDE2A
  • Target class: Enzyme

Drug Relations:

dipyridamole
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) Bioactivity details MOA
anagrelide
imidazoquinazoline derivative which lowers platelet count probably by inhibiting thrombopoiesis and reduces platelet aggregation; used for thrombocythemia Bioactivity details MOA
dicloxacillin
One of the PENICILLINS which is resistant to PENICILLINASE. Bioactivity details MOA
papaverine
An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels. Bioactivity details MOA
sildenafil
A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION. Bioactivity details MOA
vardenafil
A piperazine derivative, PHOSPHODIESTERASE 5 INHIBITOR and VASODILATOR AGENT that is used as a UROLOGICAL AGENT in the treatment of ERECTILE DYSFUNCTION. Bioactivity details MOA